Intercept Pharmaceuticals... (ICPT)
NASDAQ: ICPT
· Real-Time Price · USD
19.00
0.04 (0.21%)
At close: Nov 07, 2023, 10:00 PM
Intercept Pharmaceuticals Balance Sheet Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Cash & Equivalents | 102.74M | 136.23M | 61.4M | 50.52M | 113.19M | 58.02M | 48.32M | 84.71M | 68.33M | 145.62M | 92.95M |
Short-Term Investments | 219.98M | 277.63M | 372.19M | 435.05M | 377.66M | 346.76M | 347.38M | 334.98M | 351.8M | 268.8M | 318.24M |
Long-Term Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Long-Term Assets | 8.89M | 12.96M | 12.73M | 12.6M | 12.76M | 10.58M | 15.18M | 15.23M | 15.43M | 15.69M | 15.9M |
Receivables | 32.48M | 29.79M | 28.75M | 26.86M | 26.17M | 27.52M | 46.14M | 47.62M | 46.16M | 45.25M | 42.59M |
Inventory | 2.65M | 6.27M | 6.46M | n/a | 6.27M | 37.42M | 11.15M | n/a | 8.64M | 8.06M | 7.43M |
Other Current Assets | 27.33M | 20.85M | 21.66M | 22.36M | 28.35M | 17.31M | 24.35M | 25.29M | 21.41M | 25.38M | 26.35M |
Total Current Assets | 383.44M | 470.77M | 490.46M | 540.13M | 545.37M | 487.01M | 477.35M | 502.29M | 496.33M | 493.11M | 487.56M |
Property-Plant & Equipment | 822K | 906K | 899K | 987K | 1.28M | 1M | 10.82M | 9.5M | 11.31M | 14.43M | 16.65M |
Goodwill & Intangibles | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Total Long-Term Assets | 9.72M | 13.87M | 13.63M | 13.58M | 14.03M | 11.58M | 26M | 24.73M | 26.74M | 30.12M | 32.55M |
Total Assets | 393.16M | 484.63M | 504.08M | 553.71M | 559.4M | 498.6M | 503.36M | 527.02M | 523.07M | 523.22M | 520.11M |
Account Payables | 10.27M | 85K | 12.74M | 14.23M | 21.3M | 11.67M | 10.39M | 18.13M | 14.91M | 15.09M | 12.58M |
Deferred Revenue | n/a | -85K | n/a | n/a | n/a | n/a | 129.37M | 136.69M | 116.5M | 115.72M | 117.41M |
Short-Term Debt | n/a | 109.81M | 109.69M | 109.57M | 109.45M | n/a | 1.65M | 3.04M | 4.68M | 6.13M | 7.35M |
Other Current Liabilities | 80.58M | 77.21M | 84.69M | 106.27M | 90.83M | 139.76M | 9.63M | 8.95M | 7.77M | 8.35M | 8.89M |
Total Current Liabilities | 90.84M | 187.02M | 207.12M | 230.08M | 221.58M | 151.43M | 151.04M | 166.82M | 143.85M | 145.28M | 146.23M |
Long-Term Debt | 223.86M | 223.6M | 223.35M | 223.1M | 222.86M | 713.86M | 724.08M | 544.17M | 535.25M | 581.14M | 573.88M |
Other Long-Term Liabilities | 6.62M | 6.46M | 6.43M | 7.45M | 7.29M | 3.14M | n/a | n/a | n/a | n/a | n/a |
Total Long-Term Liabilities | 230.47M | 230.07M | 229.78M | 230.56M | 230.14M | 717M | 724.08M | 544.17M | 535.25M | 581.14M | 573.88M |
Total Liabilities | 321.32M | 417.09M | 436.9M | 460.63M | 451.73M | 868.43M | 875.12M | 710.99M | 679.1M | 726.42M | 720.11M |
Total Debt | 223.86M | 333.41M | 333.04M | 332.67M | 332.31M | 713.86M | 725.73M | 547.21M | 539.93M | 587.26M | 581.22M |
Common Stock | 42K | 42K | 42K | 42K | 41K | 30K | 30K | 30K | 30K | 33K | 33K |
Retained Earnings | -2.18B | -2.17B | -2.17B | -2.14B | -2.12B | -2.38B | -2.38B | -2.49B | -2.45B | -2.45B | -2.44B |
Comprehensive Income | -7.2M | -7.62M | -7.62M | -8.26M | -7.97M | -2.55M | -3.49M | -2.87M | -2.96M | -2.87M | -2.54M |
Shareholders Equity | 71.84M | 67.55M | 67.19M | 93.08M | 107.68M | -369.83M | -371.76M | -183.96M | -156.03M | -203.19M | -200M |
Total Investments | 219.98M | 277.63M | 372.19M | 435.05M | 377.66M | 346.76M | 347.38M | 334.98M | 351.8M | 268.8M | 318.24M |